ONC-783 / OncoC4 - LARVOL DELTA

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: OncoC4, Inc.

First-in-human • New P1 trial • Breast Cancer • Colorectal Cancer • Ovarian Cancer • Solid Tumor

Legacy OncoC4 Wholly Owned Programs (GlobeNewswire) - "ONC-782 – CAR-T cell therapy for solid and hematological malignancies: Initiation of Phase 1 Investigator Initiated Trial in China expected in 2H 2024. ONC-783 – Bispecific mAb for hematological malignancies: IND enabling studies initiated in Q2 2024. ONC-784 – ADC for solid tumors: IND enabling studies to be initiated in Q1 2025."

New P1 trial • Preclinical • Hematological Malignancies • Oncology • Solid Tumor